Q1 2026 earnings call recap: smart eyewear shipments, smartphone qualification reset, $130M+ Korea pipeline, and Q2 guidance—read now.
45m
Altimmune outlines PERFORMA Phase III MASH start in 2H 2026 and cash runway to 2029 52-week readout
"We will introduce the 2.4 milligram pemvidutide dose in Phase III," Arbet-Engels said (Chief Medical Officer), describing PERFORMA as "an event-driven study" with "the interim analysis" at "52 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results